Articles tagged with Ovarian Cancer
Researchers discovered structural changes in ovary lining cells and higher levels of Bcl-2 protein in women with ovarian cancer. These findings suggest potential early detection methods for the disease.
Researchers found that COX-2 over-expression promotes loss of basement membrane in ovarian epithelium cells, leading to disorganization and cancer. The study suggests COX-2 inhibitors may prevent cancer development by reducing basement membrane loss.
New nanotech imaging techniques offer improved precision in detecting tumors, including lymphatic drainage imaging for breast cancer, and molecular fingerprints for prostate and ovarian cancer. These advancements aim to improve diagnosis and treatment options for cancer patients.
OHSU scientists successfully transplanted ovarian tissue into monkeys, allowing the return of hormone cycles and egg production. The procedure may lead to new methods for preserving fertility in young cancer survivors.
Researchers found that retinoblastoma survivors are at higher risk of epithelial cancers such as esophagus, stomach, colon, lung, breast, cervix, or prostate, despite low radiation therapy. High folate intake is associated with a lower risk of ovarian cancer, especially among women who consume alcohol.
Phenoxodiol, a chemo-sensitizer, has shown encouraging results in treating late-stage ovarian cancer. The study found 25% response rates and synergy with chemotherapy, suggesting potential benefits for patients.
The University of Pennsylvania School of Medicine has established a first-of-its-kind peer-support helpline for individuals concerned about hereditary breast and ovarian cancer. The helpline provides direct access to trained volunteers who offer emotional support, referrals, and information on genetic counseling and risk management.
The study found that patients treated with DOXIL had a median overall survival of 63 weeks, compared to 60 weeks with topotecan. Additionally, DOXIL showed significant advantages in progression-free survival and median PFS for platinum-sensitive patients.
Researchers found correlations between cellular features and cancer development in prostate and ovarian cancers. Prostatic intraepithelial neoplasia may be a significant target for prevention strategies.
Women with BRCA1 and BRCA2 mutations have a high risk of developing breast cancer, but exercising during adolescence and maintaining a healthy weight may slow its onset. The study found that these lifestyle factors were protective regardless of birth year or family history.
A new biomarker for ovarian and uterine carcinomas has been identified, associated with poor clinical outcome. L1 glycoprotein was found in 46 of 58 ovarian cancers and 20 of 72 uterine cancers, indicating a bad prognostic factor for patient survival.
The Annual Report to the Nation on Cancer statistics shows stabilized cancer rates. A study found carboplatin-paclitaxel is better tolerated in ovarian cancer patients than cisplatin-paclitaxel. Another study linked blood transfusions with HHV-8 seropositivity, while HPV status may predict cervical lesion prognosis
A recent study found that the TGFBR1*6A gene is associated with a 26% increase in cancer risk, particularly for breast, ovarian, and colon cancers. The study's findings suggest that genetic testing and counseling can help identify individuals at high risk and provide targeted prevention strategies.
Researchers found that postmenopausal women with a higher body mass index have an increased risk of breast cancer due to elevated estrogen levels. In contrast, heavier men under age 60 or those with family history of prostate cancer may experience lower risks of developing the disease.
Researchers have identified new serum biomarkers for ovarian cancer, which may be used in conjunction with existing methods such as CA125 marker and ultrasound to improve diagnosis. These newly discovered markers show promise in detecting the disease at an early stage, leading to better treatment outcomes.
Researchers found a slightly increased risk of ovarian cancer in women with endometriosis, with a half-life increase and higher risks for younger women. In contrast, the risk of cervical cancer was reduced by roughly a third. Further investigation is needed to understand the connection between endometriosis and cancer.
Studies on prophylactic surgery for women with BRCA1/2 mutations show a significant reduction in breast and ovarian cancer risk. However, potential biases in study designs, such as confounding by indication and familial-event bias, may lead to underestimation of risk reduction.
A new biomarker, HE4, has been identified as a potential tool for early detection of ovarian cancer. The molecule is secreted into the blood and its presence can be detected in simple clinical tests.
The European Society for Medical Oncology (ESMO) presented a new drug, ET743, which has shown promising results in treating advanced ovarian cancer. In a clinical trial, the drug reduced tumors in 47% of patients, with some experiencing complete responses.
A study of 800 women with relapsing ovarian cancer found that combination chemotherapy showed a modest survival benefit compared to platinum-based chemotherapy alone. Women assigned combination therapy survived for an average of five months more than those given platinum therapy.
Two studies found that paclitaxel-based chemotherapy regimens and mini-transplants can help preserve ovarian function in younger patients. The paclitaxel regimen improved a woman's chance of regaining her ovarian function, while mini-transplants showed better results in preserving ovaries compared to high-dose chemo.
Researchers have discovered a second mechanism by which LPA promotes ovarian tumor growth through increased cyclin D1 protein levels. Additionally, the identification of PEP, a peptide fragment with vasopermeability activity, may help reduce toxicity in cancer immunotherapy. A new study also suggests that p16 inhibitors play a role in ...
Researchers at Cedars-Sinai Medical Center found that patients with hereditary BRCA-associated ovarian cancer respond better to chemotherapy, leading to improved survival. The study suggests that platinum-based chemotherapy may be more effective for these patients, and this finding may enable physicians to better plan treatment.
Researchers found that ovarian cancer cells produce collagen VI, which remodels their environment to make them more resistant to chemotherapy. This could lead to new therapeutic interventions to overcome chemotherapy resistance and improve survival rates for women with ovarian cancer.
A new study found that strengthening upper leg muscles does not protect against knee osteoarthritis and may even worsen it in people with certain knee conditions. Researchers also discovered that one-third of cancer patients who died received chemotherapy in their last six months of life.
A new generation of medical treatment is being driven by proteomics, enabling early detection of cancer and personalized therapy. The technology uses multiple high-resolution serum proteomic patterns to detect disease, with 85% accuracy in diagnosis.
Researchers found that 68% of invasive low-grade ovarian tumors and 61% of precancerous lesions carried one of the three common mutations in BRAF or KRAS. Blocking KRAS-BRAF signaling may provide more effective therapy for these cancers, which generally do not respond well to conventional chemotherapy.
Researchers at Fox Chase Cancer Center developed a transgenic mouse model of epithelial ovarian cancer, allowing scientists to study the disease's progression from early stages. The model has the potential to facilitate advances in early detection and treatment of ovarian cancer.
Researchers at Vanderbilt University Medical Center found that COX-1, not COX-2, is expressed in epithelial ovarian cancer tissue samples. This discovery may lead to the development of new treatments for ovarian cancer by blocking both COX-1 and COX-2.
Two trials found that adjuvant chemotherapy improved recurrence-free survival by 8-11% and overall survival by 5-9%, primarily benefiting patients with unrecognized residual disease. These findings suggest that adjuvant chemotherapy may be most effective in patients with non-optimal surgical staging.
Researchers at Johns Hopkins Medicine conducted a study on combined PET-CT for detecting ovarian cancer, finding that the combination showed high sensitivity (73.6%) and specificity (100%) rates. This improved detection accuracy compared to using PET scans alone.
Researchers used digital SNP analysis to detect ovarian cancer in 87% of early-stage and 95% of late-stage patients, with high total DNA amounts found in most cancer cases. The test holds promise for improved detection in a wide range of cancers.
Two new studies published in the Journal of the National Cancer Institute identified key risk factors for classical Kaposi's sarcoma and found that smoking may decrease the risk of this disease. Meanwhile, research on leptin suggests it controls breast cancer cell proliferation. Additionally, a potential screening tool for ovarian canc...
A new study published in Obstetrics and Gynecology found that aspirin inhibited ovarian tumor cell growth by as much as 68 percent. Combining aspirin with a monoclonal antibody targeting the HER-2/neu protein resulted in an even greater suppression of growth, decreasing cancer cell growth by 84 percent.
Research studies found small but statistically significant increases in cancer risks among BRCA1 mutation carriers, including colon, liver, pancreatic, and cervical cancers. Additionally, male BRCA1 mutation carriers had a slightly elevated risk of prostate cancer.
Researchers at Memorial Sloan-Kettering Cancer Center have uncovered the function of the BRCA2 protein, which interacts directly with DNA to repair genetic damage. This new understanding sheds light on how mutations in the BRCA2 gene contribute to inherited breast and ovarian cancers.
A study by Nikola Pavletich and colleagues reveals that BRCA2 protein binds to damaged DNA, repairing it. This discovery sheds light on the mechanism of breast cancer development and opens new avenues for treatment strategies.
A review highlights the association between excess body weight and increased cancer risk, particularly in colon, breast, endometrium, oesophagus, and kidney. The study suggests that alterations in hormone metabolism may play a role in this link, emphasizing the importance of weight management for cancer prevention.
Research identifies young women with breast cancer at increased risk of ovarian cancer, including those with BRCA1 and BRCA2 gene mutations. The study suggests that these women may benefit from prophylactic oophorectomy or counseling.
A new study from the International Collaborative Ovarian Neoplasm (ICON) Collaborators found that paclitaxel plus carboplatin produces similar effectiveness to other treatments for women with ovarian cancer, but with more serious side effects. Carboplatin may be considered a preferred treatment option due to its better toxicity profile.
A study found that hereditary BRCA1 and BRCA2 ovarian cancers have similar gene expression profiles to sporadic ovarian cancers. The research suggests shared molecular mechanisms between hereditary and sporadic ovarian carcinogenesis exist.
Researchers found that women at high and elevated risk of ovarian cancer are less likely to get screened than those at lower risk. Most women overestimate their risk, with only 11% correctly estimating it.
Researchers discovered significantly higher plasma ANP and proANP-(1-30) levels in women with primary ovarian cancer compared to healthy controls. The study suggests that these peptides may play a role in the development of malignant ascites associated with ovarian cancer.
A new study has found that women with the highest levels of sex hormones are at roughly twice the risk of developing breast cancer compared to those with lower levels. Additionally, researchers have discovered a potential therapy for glioblastomas using a fusion protein that shows little toxicity. Reproductive hormones have also been l...
A new study found that hormone replacement therapy, particularly estrogen alone, may increase the risk of epithelial ovarian cancer in postmenopausal women with an intact uterus. Women who used sequential progestins with estrogens had a higher risk of developing ovarian cancer compared to those who never used HRT.
Researchers found that women who received predictive genetic testing for hereditary breast and ovarian cancer took practical measures, such as regular medical exams, rather than experiencing significant distress. About 10% opted for prophylactic mastectomy, while 37% had already undergone oophorectomy before testing.
A commonly prescribed medication for treating endometriosis appears to elevate the risk of ovarian cancer, according to a new study. Women taking danazol were nearly three times more likely to develop ovarian cancer than those taking leuprolide, an anti-androgenic medication.
Researchers found that thrombocytosis correlates with more aggressive ovarian cancer and poorer response to treatment. Patients with thrombocytosis had higher CA-125 levels, advanced stage disease, and greater tendency of cancer spread.
Research found that African-American women with ovarian cancer are at a 30% increased risk of death from any cause compared to Caucasian women. The study also revealed significant differences in tumor stage, lymph node involvement, and surgery rates between the two ethnic groups. Median survival times were also shorter for African-Amer...
A study at Memorial Sloan Kettering Cancer Center found that BRCA mutation carriers are more likely to be diagnosed with early-stage breast and ovarian cancers. The research showed that intensive screening and preventive surgery can lead to the detection of these cancers, but also highlights the limitations of screening.
A new computer-based algorithm identifies a distinct proteomic pattern that distinguishes malignant from benign tumours within the ovary with 100% sensitivity and 95% specificity. This technique may help screen for ovarian cancer in high-risk and general populations.
A study led by Joellen Schildkraut at Duke University Medical Center found that oral contraceptives with higher levels of progestin may be more protective against ovarian cancer than those with lower progestin potency. Higher progestin levels were associated with a significant reduction in risk, even for short periods of use.
Researchers have identified matrix metalloproteinases as a key player in the spread of prostate cancer to the bone, offering a new target for treatment. Additionally, a genetic marker may be useful in predicting survival rates for patients with diffuse large B-cell lymphoma, while oral contraceptive use has been found to reduce ovarian...
A new study analyzing oral contraceptive use among women with epithelial ovarian cancer found a significant association between progestin levels and reduced risk. Women using low-progestin/high-estrogen contraceptives were more likely to develop ovarian cancer compared to those using high-progestin/high-estrogen contraceptives.
Researchers found that Raloxifene stimulated the growth of ovarian cancer cell lines, raising concerns about its use in ER+ patients. The study advises caution when prescribing Raloxifene to women with a history of breast cancer and ovarian cancer.
Researchers found that raloxifene stimulates cell growth in ovarian adenocarcinoma cells with estrogen receptors, increasing the risk of recurrence. The study suggests caution for women with a history of breast cancer and estrogen receptor-positive ovarian cancer.
A new study reveals that the BRCA2 gene, linked to breast and ovarian cancers, plays a previously unsuspected role in human cell division. Inactivating the BRCA2 protein delays cells' progress through mitosis, suggesting a potential new target for cancer treatment.
A new platinum-based cancer drug, BBR3464, has shown promising activity against ovarian cancer that is resistant to cisplatin. The drug, developed by Nicholas Farrell and his team, has been found to be significantly more potent than cisplatin and may offer new hope for the treatment of this devastating disease.
Researchers found that women at high risk for breast and ovarian cancer scored very low on measures of psychological distress and disorders. Despite having a high-risk profile, these women had little or no worries about developing the disease.
Researchers at the University of Pittsburgh Medical Center found that low-dose oral contraceptives offer a 40% reduced risk of ovarian cancer, similar to high-dose pills. The protection begins soon after use and continues for at least 30 years after stopping.